Vaxcyte, Inc. Stock News

Credit Suisse AG reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 13.3% during the second quarter, HoldingsChannel reports. The firm owned 11,310 shares of the companys stock after selling 1,732 shares during the quarter. Credit Suisse AGs holdings in Vaxcyte were worth $254,000 at the end of the most recent reporting period. Other institutional investors []

Vaxcyte (NASDAQ:PCVX) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Analyst Recommendations This is a breakdown of recent ratings and price targets for Vaxcyte and CytRx, as []

Zacks Investment Research cut shares of Vaxcyte (NASDAQ:PCVX) from a buy rating to a hold rating in a research note published on Wednesday, Zacks.com reports. According to Zacks, Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California. []

Vaxcyte (NASDAQ:PCVX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California. []

CAMBRIDGE, Mass. and SUZHOU, Jiangsu, China , Nov. 16, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the appointment of Teri Loxam as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Loxam will replace interim CFO Matt Gorman and will oversee finance along with several strategic and operational functions of the company. "We are delighted to welcome Teri to the Kira executive team. As Kira continues to build momentum and advance through the clinic, Teri''s wealth of experience across finance, strategy, investor relations and communications will be invaluable" said Frederick Beddingfield , MD, PhD, CEO of Kira Pharmaceuticals. "We will benefit from her strong relationships across the life sciences and investment communities and her strength in operational execution and building teams as we continue to grow and bring much needed therapies to patients." Ms.

State Street Corp cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 15.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,503,263 shares of the companys stock after selling 268,813 shares during the period. State Street Corps holdings in Vaxcyte were worth $33,838,000 []

Northern Trust Corp increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 25.7% during the second quarter, HoldingsChannel.com reports. The firm owned 365,652 shares of the companys stock after buying an additional 74,694 shares during the period. Northern Trust Corps holdings in Vaxcyte were worth $8,230,000 as of its most recent filing with the []

The average of price targets set by Wall Street analysts indicates a potential upside of 89% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines desig

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines desig

FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines desig

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines design

Two new sample breakout stocks for Week 26 with better than 10% short-term upside potential. This past week, the peak gains were in PDSB +18.6% and FSTX +6.7% with Market and S&P 500 Momentum Gauges t

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe